6703 research outputs found
Sort by
Sustainability Hub Newsletter - January 2026
No full textHappy New Year Bearcats! Check out the new Mushroom Display, the Seed library, Terracycling Stations, and Citizen Science Kits all in the Sustainability Hub! With some exciting campus news to kick off the new year, too
Making Sense: Envy in Libanius\u27 Declamation 30
Full text linkDeclamation, a genre famous for its sometimes extravagant fictions, has lately been approached as a vehicle for declaimers to reflect on realities familiar to them and their audiences. Reading Libanius\u27 rarely discussed Declamation 30 in just such a self-reflective key, I argue that it explores the mindset of the phthoneros, the envious man, as a way to make sense of risks posed by unscrupulous rivals. To shed light on this sense-making, I analyze High- and Late-Imperial emotion scripts foregrounding envy’s power to catalyze the formation of dysfunctional networks within and around competitive situations
Open Repository @ Binghamton Monthly Additions and Top Downloads - December 2025
No full textNewly added work in the Open Repository @ Binghamton (ORB) from 12/1/2025-12/31/2025. Top downloads from same time frame
Genetic Algorithm Optimization to Maximize Sensitivity of Triboelectric MEMS Accelerometers
No full textA genetic algorithm is used to optimize the sensitivity of a triboelectric MEMS accelerometer fabricated using CMOS-compatible processes. The optimization focuses on the structural parameters of an awl-shaped serpentine microspring (ASSM) connected to the proof mass. Constraints are defined by microfabrication standards and the available chip area. Three different constraint problems are considered, and the algo- rithm yields designs with maximized sensitivity in each case. Simulations under various sinusoidal vibration scenarios show that the optimized designs significantly outperform the previous version, achieving a 2.72× improvement at 1000 Hz and up to 20× at 500 Hz
Campus Dialogue Guidebook 2025
Full text linkThis guidebook\u27s purpose is to understand and address the potential of dialogue for our Binghamton campus community. It shares the background of dialogue on campus, describes case studies of dialogue work on campus, offers “things to do,” and finally suggests some ways of measuring effective dialogue. This guidebook is written primarily by students, and for students to use. Students at Binghamton University are our primary audience. The principles in this guidebook may be applicable across other campuses in similar environments. This guidebook is put together in a way that shows what kind of dialogue has been happening and not happening, and what can be learned from these activities. We then highlight types of dialogue work that can take place and campus resources that can support this work.https://orb.binghamton.edu/books/1003/thumbnail.jp
Open Repository @ Binghamton Monthly Additions and Top Downloads - August 2025
Full text linkNewly added work in the Open Repository @ Binghamton (ORB) from 8/1/2025-8/31/2025. Top downloads from same time frame
Phenytoin dosing practices for traumatic brain injury seizure prophylaxis in the absence of the availability of therapeutic drug monitoring in Uganda: A chart review study
Full text linkPhenytoin is commonly used for seizure prophylaxis in patients with traumatic brain injury at Mulago National Referral Hospital in Kampala, Uganda. However, phenytoin therapeutic drug monitoring is not available in this low-resource setting. Anecdotes of breakthrough seizures in patients on phenytoin from healthcare providers at this institution prompted this quality improvement study. This study aimed to characterize prescribing practices for phenytoin and other antiepileptic drugs and then identify improvement strategies for seizure prophylaxis in patients with traumatic brain injury. A retrospective medical chart review was conducted to retrieve information, including dosage and timing of all antiepileptic drugs prescribed in relation to admission and surgery, duration of therapy, doses documented as administered to the patient, adverse reactions, and laboratory test results. Of 28 patient charts reviewed, 12 different regimens of phenytoin were prescribed, 250 mg IV twice daily was the most common, and only 28.6% of patients had loading doses. The duration of antiepileptic drug use was \u3e7 days in 89% of patients. Lamotrigine was also prescribed in 57.1% of patients, and the starting doses were higher than recommended in drug dosing references. Administration of antiepileptic drugs was charted in \u3c 50% of patients. This study revealed opportunities to improve seizure prophylaxis, including standardization of phenytoin prescribing with loading doses, reducing the length of therapy to no more than 7 days, discontinuing the use of lamotrigine, and recognizing the benefits of a clinical pharmacist as part of the healthcare team to assist with pharmacovigilance
Experimental Investigation of 3D Printed TPU Triboelectric Composites for Biomechanical Energy Conversion in Knee Implants
Full text linkAlthough total knee replacements have an insignificant impact on patients’ mobility and quality of life, real-time performance monitoring remains a challenge. Monitoring the load over time can improve surgery outcomes and early detection of mechanical imbalances. Triboelectric nanogenerators (TENGs) present a promising approach as a self-powered sensor for load monitoring in TKR. A TENG was fabricated with dielectric layers consisting of Kapton tape and 3D-printed thermoplastic polyurethane (TPU) matrix incorporating CNT and BTO fillers, separated by an air gap and sandwiched between two copper electrodes. The sensor performance was optimized by varying the concentrations of BTO and CNT to study their effect on the energy harvesting behavior. The test results demonstrate that the BTO/TPU composite that has 15% BTO achieved the maximum power output of 11.15 μW, corresponding to a power density of 7 mW/m2, under a cyclic compressive load of 2100 N at a load resistance of 1200 MΩ, which was the highest power output among all the tested samples. Under a gait load profile, the same TENG sensor generated a power density of 0.8 mW/m2 at 900 M Ω. By contrast, all tested CNT/TPU-based TENG produced lower output, where the maximum generated apparent power output was around 8 μW, corresponding to a power density of 4.8 mW/m2, confirming that using BTO fillers had a more significant impact on TENG performance compared with CNT fillers. Based on our earlier work, this power is sufficient to operate the ADC circuit. Furthermore, we investigated the durability and sensitivity of the 15% BTO/TPU samples, where it was tested under a compressive force of 1000 N for 15,000 cycles, confirming the potential of long-term use inside the TKR. The sensitivity analysis showed values of 37.4 mV/N for axial forces below 800 N and 5.0 mV/N for forces above 800 N. Moreover, dielectric characterization revealed that increasing the BTO concentration improves the dielectric constant at the same time reducing the dielectric loss, with an optimal 15% BTO concentration exhibiting the most favorable dielectric properties. SEM images for BTO/TPU showed that the 10% and 15% BTO/TPU composites showed better morphological characteristics with lower fabrication defects compared with higher filler concentrations. Our BTO/TPU-based TENG sensor showed robust performance, long-term durability, and efficient energy conversion, supporting its potential for next-generation smart total knee replacements
Open Repository @ Binghamton Monthly Additions and Top Downloads - October 2025
Full text linkNewly added work in the Open Repository @ Binghamton (ORB) from 10/1/2025-10/31/2025. Top downloads from same time frame
Microfluidic blood-milk barrier and physiologically based pharmacokinetic model to predict lofexidine secretion into breast milk
Full text linkIntroduction: Lofexidine (LUCEMYRA ®) is the only FDA-approved, non-opioid, non-addictive treatment for opioid withdrawal symptoms, crucial for postpartum and pregnant women affected by the opioid crisis. Despite its clinical importance, data on its secretion into breast milk is limited. This study aims to develop a novel, microfluidic-based blood-milk-barrier on a chip model, a static human mammary cell transwell model, and a physiologically based pharmacokinetic (PBPK) lactation model to estimate the breast milk secretion of lofexidine, thereby ensuring maternal and infant safety and improving withdrawal management. Methods: A novel microfluidic device was developed to build a mammary epithelium-on-a-chip model, and a transwell plate was used to develop a static mammary epithelium using a human noncarcinogenic mammary epithelial cell (MEC) population that can form an integrated barrier with tight junctions. Both models were used to evaluate the transfer of lofexidine through the in vitro mammary cell barrier. The fraction of unbound lofexidine in the breast milk was determined by a Rapid Equilibrium Dialysis (RED) assay. Eleven approaches, including a novel, previously published in vitro to in vivo extrapolation (IVIVE) approach and various other approaches, were used to estimate milk-to-plasma (M/P) ratios of lofexidine. A whole-body lactation PBPK model was built using Simcyp® simulator v22 and used to predict the concentration-time profiles of lofexi-dine in both human plasma and breast milk. Results: A subpopulation of human normal mammary epithelial MCF10A cells (named MCF10A-TJ) was identified to form an integrated barrier that reaches trans-epithelial electrical resistance (TEER) values of over 1000 Ω-cm2 by culturing with in-house designed maintenance and boosting medium. The microfluidic device-based mammary epithelium-on-a-chip model generated slightly higher lofexidine permeability values than the static transwell mammary epithelial cell model. The predicted milk-to-plasma (M/P) ratio of lofexidine ranged from 0.40 to 15.88. Four approaches estimated an M/P ratio below 1, while seven predicted values above 1, mostly between 1.35 and 5.48. The whole-body lactation PBPK model predicted the concentration-time profile of lofexidine in breast milk, with an estimated M/P ratio of approximately 2.0. This value falls within the mid-range of the predictions obtained from all eleven methods. Conclusion: This study introduces comprehensive and novel approaches to predict lofexidine secretion into breast milk. Most predictions suggest higher lofexidine concentration in milk than in plasma, raising potential safety concerns for opioid withdrawal management. Further pharmacokinetic clinical lactation studies are needed to validate these predictions